Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Accumulation During Multiple Dosing: Repetitive IV Injections01:21

Drug Accumulation During Multiple Dosing: Repetitive IV Injections

256
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
256
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

222
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
222
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

266
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
266
Drug Delivery: Overview01:16

Drug Delivery: Overview

730
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
730

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multicomponent reactions for protein tyrosine phosphatase inhibitors.

Molecular diversity·2026
Same author

Multiplexed cytokine and antigen mRNA administration generates durable anti-tumor immunity against pancreatic cancer.

Nature communications·2026
Same author

Marine exometabolites correlate with benthic fungal diversity and community structure in the South China Sea.

Microbiology spectrum·2026
Same author

ADCE-T02 - a Next Generation Antibody Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability.

Molecular cancer therapeutics·2026
Same author

Research on improved models for facial expression recognition in mice with abnormal glucose metabolism.

Scientific reports·2026
Same author

Correction to "Multicomponent Reaction-Enabled Semisynthesis of Taxanes Yields an Analogue with Reduced Chemotherapy-Induced Neuropathy".

JACS Au·2025

Related Experiment Video

Updated: Jan 17, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.2K

SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations.

Wenlong Sun1, Weining Weng2, Jing Shi3

  • 1HuaO Therapeutics, Shanghai 200441, China.

Bioconjugate Chemistry
|September 17, 2025
PubMed
Summary

Synergistic Payload-Antibody Ratiometric Conjugates (SPARCs) enable precise combination cancer therapy by delivering multiple drugs at optimized ratios. This approach enhances efficacy and reduces toxicity compared to traditional methods.

More Related Videos

Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.9K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.5K

Related Experiment Videos

Last Updated: Jan 17, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
11:02

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

8.2K
Optimization of Radiochemical Reactions using Droplet Arrays
10:54

Optimization of Radiochemical Reactions using Droplet Arrays

Published on: February 12, 2021

3.9K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

19.5K

Area of Science:

  • Oncology
  • Pharmacology
  • Bioconjugation Chemistry

Background:

  • Drug combinations are crucial in oncology but often limited by toxicity and poor targeting.
  • Antibody-drug conjugates (ADCs) deliver single payloads but struggle with multipayload delivery.
  • Existing multipayload ADCs lack knowledge of payload synergy and face complex engineering challenges.

Purpose of the Study:

  • To design a novel multipayload ADC platform, Synergistic Payload-Antibody Ratiometric Conjugate (SPARC), for precision combination therapy.
  • To elucidate payload ratio-dependent pharmacology and toxicology for optimized drug combinations.
  • To develop a programmable platform for assembling SPARCs with tunable payload ratios and high drug-antibody ratios (DAR).

Main Methods:

  • Synthesized Multi-T1000 payload (MTP) moieties using orthogonal azide-alkyne click chemistry.
  • Conjugated MTPs to native antibodies or engineered cysteines of THIOMABs to create SPARCs with 2-6 payloads.
  • Evaluated SPARC stability, homogeneity, antibody binding, in vivo pharmacology, and toxicology.

Main Results:

  • Achieved programmable SPARC assembly with 2-6 payloads, DAR up to 30, and tunable payload ratios (1-10).
  • SPARCs demonstrated stability, homogeneity, and retained antibody binding.
  • In vivo studies showed reduced off-target toxicity and enhanced efficacy due to synchronized payload delivery and synergistic interactions.
  • SPARCs combining Topoisomerase I (TOP1) and DNA Damage Response (DDR) inhibitors outperformed single-payload ADCs and free-drug combinations.

Conclusions:

  • SPARC represents a transformative approach to precision combination therapy in oncology.
  • This platform enables rational drug codelivery, potentially reusing abandoned drugs as payloads.
  • SPARCs offer improved safety profiles and efficacy, addressing unmet needs in cancer treatment and other diseases.